-- Company's third bi-specific DART® molecule, MGD010, in clinical testing
-- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015
"I am very pleased to announce the clearance for clinical testing of MGD011, following our recent IND submission to the
Margetuximab is an Fc-optimized monoclonal antibody that targets HER2. Recent highlights include:
Phase 3 Metastatic Breast Cancer Study: The Company remains on track to commence SOPHIA, a Phase 3 pivotal study in approximately 530 subjects, in the third quarter of 2015. This study is planned to evaluate margetuximab plus chemotherapy against trastuzumab plus chemotherapy in third-line metastatic breast cancer patients with HER2 expression at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification, subject to completion of further regulatory review.
MacroGenicsprojects that it will take approximately three years to complete this study, which will include an interim futility analysis.
ASCO Presentation of Phase 1 Data:
MacroGenicsplans to present margetuximab Phase 1 clinical data at the 2015 American Society of Clinical Oncology(ASCO) Annual Meeting in a poster discussion.
- Gastroesophageal Cancer Opportunity: The Company remains on track to initiate a Phase 1/2 combination study in gastroesophageal cancer starting in the fourth quarter of 2015.
MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules involved in immune regulation. Recent highlights include:
- Recruiting Additional Monotherapy Expansion Cohorts: As previously disclosed, the Company is recruiting patients in multiple additional MGA271 monotherapy expansion cohorts across various tumor types, including triple-negative breast cancer, head and neck cancer, renal cell cancer, melanoma (in patients who have failed a checkpoint inhibitor), non-small cell lung cancer and bladder cancer.
- Combination Studies: MacroGenics is currently enrolling a study of MGA271 in combination with ipilimumab in patients with B7-H3 positive melanoma, lung, and head and neck cancers. In addition, the Company will be initiating a study of MGA271 in combination with an anti-PD-1 antibody in patients with melanoma, non-small cell lung carcinoma and squamous cell carcinoma of the head and neck later this year.
Presentation of Phase 1 Data: In the second half of 2015,
MacroGenicsplans to present Phase 1 clinical data for MGA271.
MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells. The primary mechanism of action of MGD006 is its ability to redirect T cells, via their CD3 component, to kill CD123-expressing cells. MacroGenics continues to enroll patients in the dose escalation portion of a Phase 1 study of MGD006 for the treatment of acute myeloid leukemia.
MGD007 is a humanized DART molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. gpA33 is a gastrointestinal antigen with high expression in colorectal cancer.The primary mechanism of action of MGD007 is its ability to redirect T cells, via their CD3 component, to kill gpA33-expressing cells. MacroGenics continues to enroll patients in the dose escalation portion of a Phase 1 study of MGD007 for the treatment of colorectal cancer.
MGD010 is a humanized DART molecule that simultaneously targets CD32B and CD79B, two B-cell surface proteins. MGD010 is being developed for the treatment of autoimmune disorders and is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells. MacroGenics initiated a Phase 1a study in normal healthy volunteers during the first quarter of 2015, which triggered a milestone payment of
MGD011 is a humanized DART molecule that targets both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. MGD011 is designed to redirect T cells, via their CD3 component, to eliminate cells expressing CD19, a specific marker expressed in B-cell hematological malignancies. MGD011 has been engineered to address half-life challenges posed by other programs targeting CD19 and CD3, allowing for convenient dosing regimens in the clinical setting.
First Quarter 2015 Financial Results
Cash Position: Cash and cash equivalents as of
March 31, 2015were $263.1 million, compared to $157.6 millionas of December 31, 2014. In the first quarter of 2015, MacroGenicsclosed a previously announced global collaboration and license agreement for MGD011 with Janssenand received a $50 millionupfront license fee. Johnson & Johnson Innovation - JJDC, Inc.also invested $75 millionwith the purchase of new shares of MacroGenicscommon stock at a price of $39.00per share.
Revenue: Total revenues, consisting primarily of revenue from collaborative research, were
$71.3 millionfor the quarter ended March 31, 2015, including $62.3 millionassociated with the Janssencollaboration, compared to $14.7 millionfor the quarter ended March 31, 2014. Collaborative research revenue includes the recognition of deferred revenue from payments received in previous periods as well as payments received during the year.
R&D Expenses: Research and development expenses were
$21.5 millionfor the quarter ended March 31, 2015, compared to $14.6 millionfor the quarter ended March 31, 2014. This increase was primarily due to the clinical study preparations for two product candidates and increased activity related to IND preparation for a preclinical program.
G&A Expenses: General and administrative expenses were
$4.7 millionfor the quarter ended March 31, 2015, compared to $3.3 millionfor the quarter ended March 31, 2014. This increase was primarily due to higher stock-based compensation expense and labor costs as well as information technology-related expenses.
Net Income (Loss): Net income was
$45.1 millionfor the quarter ended March 31, 2015, compared to net loss of $3.1 millionfor the quarter ended March 31, 2014. Excluding the effects of the Janssencollaboration, the Company would have had a net loss of $17.2 millionfor the quarter ended March 31, 2015.
Shares Outstanding: Shares outstanding as of
March 31, 2015were 30,024,535, including the 1,923,077 shares issued to Johnson & Johnson Innovation - JJDC, Inc., in January 2015.
Conference Call Information
The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
|CONSOLIDATED BALANCE SHEET DATA|
|(Amounts in thousands)|
|Cash and cash equivalents||$ 263,134||$ 157,591|
|Total stockholders' equity||230,993||121,286|
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)|
|(Amounts in thousands, except share and per share data)|
Three Months Ended
|Revenue from collaborative research||$ 71,165||$ 14,401|
|Costs and expenses:|
|Research and development||21,464||14,569|
|General and administrative||4,683||3,258|
|Total costs and expenses||26,147||17,827|
|Income (loss) from operations||45,132||(3,108)|
|Other income (expense)||(3)||-|
|Net comprehensive income (loss)||$ 45,129||$ (3,108)|
|Basic net income (loss) per common share||
|Diluted net income (loss) per common share||
|Basic weighted average common shares outstanding||29,415,768||26,262,356|
|Diluted weighted average common shares outstanding||31,684,174||26,262,356|
|SUMMARY OF NON-GAAP ADJUSTMENTS|
|(Amounts in thousands, except share and per share data)|
Three months ended
|Total revenues||$ 71,279||$ 62,308||$ 8,971|
|Income (loss) from operations||45,132||(62,308)||(17,176)|
|Net comprehensive income (loss)||45,129||(62,308)||(17,179)|
|Basic net income (loss) per common share||$ 1.53||$ (2.12)||$ (0.58)|
|Diluted net income (loss) per common share||$ 1.42||$ (2.12)||$ (0.58)|
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the
Jim Karrels, Senior Vice President, CFO MacroGenics, Inc.1-301-251-5172, email@example.com Karen Sharma, Vice President MacDougall Biomedical Communications1-781-235-3060, firstname.lastname@example.org
News Provided by Acquire Media